Interestingly, local administration of the selective CB2 agonist—JWH133 resulted in considerable regression of glioma by inducing glioma cell death (12) and suppressing the production of vascular endothelial growth factor (VEGF) in glioma cells (13). Here, VEGFA is linked to central nervous system cancer.